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A B S T R A C T
Background
Clinical practice guidelines suggest that magnetic resonance imaging (MRI) of the brain should be performed at certain time points
or intervals distant from diagnosis (interval or surveillance imaging) of cerebral glioma, to monitor or follow up the disease; it is not
known, however, whether these imaging strategies lead to better outcomes among patients than triggered imaging in response to new
or worsening symptoms.
Objectives
To determine the eGect of diGerent imaging strategies (in particular, pre-specified interval or surveillance imaging, and symptomatic or
triggered imaging) on health and economic outcomes for adults with glioma (grades 2 to 4) in the brain.
Search methods
The Cochrane Gynaecological, Neuro-oncology and Orphan Cancers (CGNOC) Group Information Specialist searched the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE and Embase up to 18 June 2019 and the NHS Economic Evaluation Database (EED) up
to December 2014 (database closure).
Selection criteria
We included randomised controlled trials, non-randomised controlled trials, and controlled before-aHer studies with concurrent
comparison groups comparing the eGect of diGerent imaging strategies on survival and other health outcomes in adults with cerebral
glioma; and full economic evaluations (cost-eGectiveness analyses, cost-utility analyses and cost-benefit analyses) conducted alongside
any study design, and any model-based economic evaluations on pre- and post-treatment imaging in adults with cerebral glioma.
Data collection and analysis
We used standard Cochrane review methodology with two authors independently performing study selection and data collection, and
resolving disagreements through discussion. We assessed the certainty of the evidence using the GRADE approach.
Main results
We included one retrospective, single-institution study that compared post-operative imaging within 48 hours (early post-operative
imaging) with no early post-operative imaging among 125 people who had surgery for glioblastoma (GBM: World Health Organization
(WHO) grade 4 glioma). Most patients in the study underwent maximal surgical resection followed by combined radiotherapy and
temozolomide treatment. Although patient characteristics in the study arms were comparable, the study was at high risk of bias overall.
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Evidence from this study suggested little or no diGerence between early and no early post-operative imaging with respect to overall survival
(deaths) at one year aHer diagnosis of GBM (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.61 to 1.21; 48% vs 55% died, respectively;
very low certainty evidence) and little or no diGerence in overall survival (deaths) at two years aHer diagnosis of GBM (RR 1.06, 95% CI 0.91
to 1.25; 86% vs 81% died, respectively; very low certainty evidence). No other review outcomes were reported.
We found no evidence on the eGectiveness of other imaging schedules. In addition, we identified no relevant economic evaluations
assessing the eGiciency of the diGerent imaging strategies.
Authors' conclusions
The eGect of diGerent imaging strategies on survival and other health outcomes remains largely unknown. Existing imaging schedules
in glioma seem to be pragmatic rather than evidence-based. The limited evidence suggesting that early post-operative brain imaging
among GBM patients who will receive combined chemoradiation treatment may make little or no diGerence to survival needs to be further
researched, particularly as early post-operative imaging also serves as a quality control measure that may lead to early re-operation if
residual tumour is identified. Mathematical modelling of a large glioma patient database could help to distinguish the optimal timing of
surveillance imaging for diGerent types of glioma, with stratification of patients facilitated by assessment of individual tumour growth
rates, molecular biomarkers and other prognostic factors. In addition, paediatric glioma study designs could be used to inform future
research of imaging strategies among adults with glioma.
P L A I N   L A N G U A G E   S U M M A R Y
Brain scans for people with cerebral gliomas
Background
Gliomas are brain tumours arising from the supporting brain tissues. They are termed low grade (WHO 1 and 2) or high grade (WHO 3
and 4), depending on their cell activity and how aggressive the tumour is. Gliomas are diagnosed in 4 to 11 people for every 100,000
each year, more commonly in high-income countries. Whilst low-grade, slow-growing gliomas may be watched before deciding the most
appropriate treatment (active surveillance), most people with gliomas will eventually undergo surgery to safely remove as much of the
tumour as possible. AHer surgery, other treatments such as radiation and chemotherapy might be suitable, depending on the tumour grade
and other aspects. The standard treatment for grade 4 tumours, known as glioblastomas, is radiotherapy and an anti-cancer medicine
(temozolomide).
In people with slow-growing tumours, magnetic resonance imaging (MRI) scans are usually performed at regular intervals to check tumour
growth before treatment. AHer surgery to remove gliomas of any grade, regular scans check how tumours are responding to added
treatment and whether the disease is coming back. Scans are mostly performed at set timings rather than happening due to changes in a
patient's condition. This is known as surveillance imaging. An MRI is oHen done within three days of high-grade glioma surgery to check
how much tumour has been removed.
Instead of having regular scans, you could scan when someone experiences changes suggesting that the tumour has grown. This is known
as symptomatic or triggered imaging. Brain scans can be expensive and regular scans when a person feels well may cause anxiety. Also, if
a brain scan will not change treatment it might not be needed. We undertook this review because it is not known whether diGerent timings
of imaging have an impact on the time a person will survive aHer diagnosis. We also wanted to see which approach was better in identifying
concerning tumour changes, and eGects on quality of life, anxiety and depression. We also searched to see which approach would provide
better value to the health service.
How we conducted the review and what we found
We looked for studies involving adults with gliomas that compared current practice of doing scans at specific time points with other
approaches. We found only one study meeting our criteria. This was from a cancer centre in the USA, looking at glioblastoma patients
(those with the most aggressive gliomas) who had been treated between 2006 and 2016. The study involved 125 people and split them into
those scanned within two days of surgery (early scan) with those who were not. They showed that doing the early scan made no change
to the chance of being alive at one and two years aHer diagnosis. This might have been because the early scans were not used to change
treatments, which mainly were to receive standard radiotherapy and temozolomide, and we could not tell if the patients' surgeon(s) were
diGerent or had diGerent approaches to care. We judged this suggestion of little change in survival time with or without early scanning to
be very uncertain. The number of people included over 10 years was small, and the decision whether or not to have a scan aHer surgery was
based on surgeon's choice. It was not clear whether the surgeon(s) involved or their approaches to care diGered, nor whether a person's
care might have been changed in light of early imaging. The other search did not find any studies looking at the value of diGerent imaging
approaches.
Conclusions
We still do not know whether doing scans regularly at specific times aHer glioma diagnosis changes how well patients do. The limited
evidence, suggesting early scans aHer operations do not aGect survival, is unreliable and more research is needed, especially as early scans
Interval brain imaging for adults with cerebral glioma (Review)
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may also help surgeons improve their practice, and decide whether to repeat the operation earlier than they might otherwise have chosen
to do.
The best timings and reasons for scanning brain gliomas in adults are not known. Lessons might be learned from studies involving children,
and by looking at large collections of clinical trials. It is also important to study the potential costs and benefits of diGerent strategies.
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Summary of findings for the main comparison.
Early post-operative MRI compared with no early post-operative MRI for glioblastoma
Patient or population: adults with glioblastoma
Settings: tertiary care
Intervention: early post-operative MRI (within 48 hours of tumour resection)
Comparison: no early post-operative MRI
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
No early MRI Early MRI
Relative effect
(95% CI)
No of Partici-
pants
(studies)
Quality of the evi-
dence
(GRADE)
Overall survival (deaths at 1 year) 554 per 1000 476 per 1000
(338 to 670)
(RR 0.86, 95% CI 0.61 to
1.21)
125 (1) ⊕⊕⊝⊝
very low1
Overall survival (deaths at 2 years) 804 per 1000 852 per 1000
(732 to 1000)
(RR 1.06, 95% CI 0.91 to
1.25)
125 (1) ⊕⊕⊝⊝
very low1
Progression free survival no evidence
Anxiety no evidence
Quality of life no evidence
*The basis for the assumed risk is the risk in the control group of the included study. The corresponding risk (and its 95% CI) is based on the assumed risk in the compari-
son group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1Downgraded for risk of bias, as the patients in this study received the interventions based on surgeons' preferences and discretion
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B A C K G R O U N D
Description of the condition
Brain and other central nervous system (CNS) tumours are less
common than many other cancers, accounting for around 1.9%
of new cancer diagnoses annually and approximately 2.3% or
189,382 deaths worldwide in 2012 (GLOBOCAN 2012). In terms
of years of potential life lost (YPLL), in the USA malignant brain
and other CNS tumours have the greatest impact of any cancer
in adults, a reflection of their age of onset and the comparatively
short survival time of some of the most common types (Rouse
2016). Gliomas are brain tumours that are believed to arise
from progenitor glial lineage cells derived from neural stem cells
(although this is still a matter of debate). They occur at an
annual incidence of four to 11 people per 100,000 and are more
frequent in high-income, industrialised countries (Ohgaki 2009).
Gliomas are graded 1 to 4 by the World Health Organization
(WHO), according to their malignancy or malignant potential. The
2007 WHO classification system (Louis 2007), used in completed
clinical studies since 2007, graded gliomas based on histological
characteristics only. However in the 2016 WHO classification
system, which is likely to be used in future studies, grading for
the first time depends on both histological and molecular features,
for example isocitrate dehydrogenase (IDH) status, chromosome
1p/19q co-deletions, and other genetic parameters (Louis 2016).
Molecular characterisation is now the default assessment where
available, and supersedes the histological phenotype. Using the
2007 WHO classification, gliomas graded 1 and 2 are referred to as
low-grade gliomas: these included pilocytic astrocytomas (grade
1) which represent a distinct clinical entity with low malignant
potential; and diGuse astrocytomas, oligodendrogliomas and
mixed oligoastrocytomas (grade 2). High-grade gliomas included
anaplastic astrocytomas, anaplastic oligodendrogliomas (grade
3) and glioblastoma multiforme (GBM; grade 4). The 2016
classification separates pilocytic astrocytoma into "other astrocytic
tumours" and it is the category of "diGuse astrocytic and
oligodendroglial tumours" comprising grades 2 to 4 that are the
focus of this review. As of 2016, true mixed oligoastrocytomas are
now exceedingly rare, since detection of both canonical molecular
signatures is required within the same tumour. Such changes are
indicative of the challenges faced in interpreting previous studies
in glioma in the current clinical context. While in the literature
malignant transformation rates vary between approximately one
in four to three in four, there is a significant risk of malignant
transformation of low-grade to high-grade glioma and the potential
for, and timing of, malignant transformation is not well understood.
Grades correspond to prognosis. Grade 1 has a good prognosis
and can oHen be cured with surgery alone; grade 2 gliomas have
a median survival of five to fiHeen years; anaplastic astrocytoma
(grade 3) between two and five years; whereas grade 4 has
the poorest prognosis, with a median survival of one to two
years in the era of safe maximal resection and temozolomide
chemoradiotherapy (Louis 2007). Even in the molecular era,
therefore, tumour grade is a key factor in deciding how to treat
gliomas. It also plays a role in determining the timing and
frequency of radiologic follow-up. It is increasingly recognised,
however, that molecular characteristics also play a role, with
1p/19q co-deleted IDH mutant oligodendrogliomas having a more
favourable prognosis than 1p/19q intact IDH mutant diGuse
astrocytomas, which in turn demonstrate longer survival than
IDH-wildtype diGuse astrocytomas. It is expected that further
molecular characterisation of the last group will oGicially enter
WHO classification in a future update, identifying those with GBM-
like markers, which can be managed in a similar way to high-
grade glioma despite the traditional histological appearance of
low-grade glioma. It is currently unclear how these molecular
features will dovetail with traditional 'high risk' stratification of low-
grade glioma (e.g. Pignatti 2002), such as aged older than 40 years
and achieving less than gross total resection. This evolving clinical
and molecular risk stratification will have implications for future
guidelines and research in how gliomas are treated and imaged.
Description of the intervention
Magnetic resonance imaging (MRI) or computed tomography (CT)
of the brain is key to the diagnosis of a glioma. MRI is the preferred
technique as it has superior soH tissue resolution and gives a
better definition of tumour extent (NCCN 2018; NCI 2017; NICE
2006). These imaging techniques can, however, be challenging
to interpret when distinguishing the type of tumour and grade,
or occasionally when diGerentiating tumours from inflammatory
or ischaemic lesions (e.g. following a stroke or radiation). This is
particularly the case during follow-up of treated gliomas where
the most commonly used criterion of enlarging contrast-enhancing
lesions can be non-specific and is also seen with treatment-related
eGects such as pseudoprogression or radiation necrosis. Other
imaging techniques, such as magnetic resonance spectroscopy
(MRS), MR perfusion imaging, single photon emission computed
tomography (SPECT) and positron emission photometry (PET),
can be used to provide additional information prior to surgery
to improve the accuracy of histopathological examination and
provide increased specificity during follow-up, although variation
in training, performance, and availability of these techniques limits
widespread use (NCCN 2018; NICE 2018).
In addition to primary diagnosis, brain imaging is an integral
part of management and follow-up of glioma and informs
treatment decisions in the period immediately aHer diagnosis.
AHer surgery, MRI has been shown to more accurately identify
the extent of residual tumour — an important prognostic factor
— than the neurosurgeon's estimation (Albert 1994). The National
Comprehensive Cancer Network (NCCN) guidelines recommends
post-operative brain MRI within 24 to 72 hours of glioma surgery for
this purpose (NCCN 2018). Imaging is also used universally to assess
the tumour response among people actively receiving treatment
and, in clinical studies of glioma treatment, imaging before the start
of adjuvant therapy is common practice, which can serve as the
baseline for detecting tumour progression (e.g. Malmström 2017;
Wick 2012). In a study of bevacizumab for glioblastoma, performing
a follow-up MRI from as early as four weeks aHer starting treatment
has been reported to be an accurate predictor of both treatment
response and survival (Field 2017).
Outside the immediate treatment period, people with glioma will
also be oGered imaging at regular intervals. Interval imaging,
sometimes referred to as surveillance imaging, refers to imaging
at defined future time points as requested by the clinical team,
for monitoring tumour appearance. Outside periods of treatment,
this is referred to as active surveillance. It is not known at that
specific time point in the future whether the person aGected will be
less symptomatic, the same (i.e. stable), or be more symptomatic
at the imaging visit. The imaging is not, therefore, based on a
clinical deterioration of the person’s symptoms and signs. An
Interval brain imaging for adults with cerebral glioma (Review)
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alternative approach to interval imaging would be to arrange
imaging when a person, carer, or clinician notes a deterioration
in signs or symptoms (or both); this is called symptomatic or
triggered imaging. Current practice represents a combination of
these, with surveillance imaging as the default, and triggered
imaging when a significant clinical change is encountered between
planned imaging visits.
There are several scenarios in which interval imaging is used among
people with a glioma. Before surgical biopsy or treatment among
those with a suspected low-grade glioma, interval imaging might
be performed to ensure that the actual growth of the tumour is
not faster than that expected from the anticipated grade. It might
also be considered for lesions with radiological features of a low-
grade tumour that do not necessitate immediate treatment, for
example an optic pathway glioma (NICE 2018). AHer treatment,
interval imaging is usually performed for both low-grade and high-
grade gliomas to check for any interval tumour growth and to
determine whether treatment has been successful at slowing or
halting growth. The NCCN recommends MRI follow-up of low-grade
gliomas every three to six months for five years, then at least
annually thereaHer; whereas for GBM, an MRI two to six weeks
aHer radiotherapy, then every two to four months for three years,
then every six months indefinitely, is recommended (NCCN 2018).
Suggested imaging intervals in National Institute for Health and
Clinical Excellence (NICE) guidance are slightly longer (e.g. for GBM
the suggested intervals are three to six months up to two years aHer
treatment, then six to 12 months up to three years, then annually
indefinitely (Table 1)). In general, though, for both low-grade and
high-grade gliomas, interval duration increases over time from
diagnosis and treatment.
SPECT and PET can also be helpful in the post-treatment scenario
to distinguish between tumour recurrence and treatment eGects
such as pseudoprogression and radiation necrosis (NCCN 2018; NCI
2017). This is an important role of imaging, since treatment-related
eGects can be symptomatic, and either neutral (radiation necrosis)
or favourable (pseudoprogression) when deciding on whether to
maintain or change treatment.
Why it is important to do this review
To our knowledge, there are no existing systematic reviews of this
topic. The relative benefits of surveillance imaging, if any, over
other imaging approaches among people with glioma are currently
not known. In addition, whilst clinical guidelines recommend
routine MRI follow-up or active monitoring, the optimal frequency
of routine active monitoring has not been rigorously established.
In existing clinical practice guidelines, it is recommended that the
frequency of routine active monitoring decreases with time (NCCN
2018; NICE 2018; SEOM 2017). However, since low-grade glioma can
present at any time during a natural history that might span over
a decade, and the risk and timing of recurrence is unpredictable,
frequent imaging early on might be unnecessary.
Diagnostic uncertainties raised by brain imaging performed within
the first three to six months due to treatment, such as true tumour
progression versus pseudoprogression, might increase patient and
clinician anxiety during this monitoring period, and negatively
aGect quality of life. In addition, potential health risks from repeat
gadolinium administration has come under scrutiny recently,
especially in people with longer-term survival. Brain imaging is
potentially costly, both for the health system and the individual
and, while performing it routinely has not been robustly assessed
from a health economic perspective, there are also limited data on
the psychological impact experienced by patients and carers during
treatment from repeated cycles of imaging and uncertainty while
waiting on the result.
Surveillance imaging was established as a follow-up strategy
early in the development of readily available non-invasive
imaging investigation, based on expert consensus. This basis has
become questionable, since this expert opinion was derived from
experience gained during the 'pre-molecular' era when recent
standards of care for glioma treatment were not yet available or
established. The aim of this review, therefore, is to systematically
evaluate the evidence for diGerent imaging strategies to inform
clinical practice guidelines and research agendas.
O B J E C T I V E S
To determine the eGect of diGerent imaging strategies (in particular,
pre-specified interval or surveillance imaging, and symptomatic or
triggered imaging) on health and economic outcomes for adults
with glioma (grades 2 to 4) in the brain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), non-randomised controlled
trials (NRCTs), and controlled before-aHer studies (CBAS) with
concurrent comparison groups.
Full economic evaluations (cost-eGectiveness analyses, cost-utility
analyses and cost-benefit analyses), conducted alongside any
study design and any model-based economic evaluations.
Types of participants
Adults with a histologically confirmed diagnosis of cerebral glioma
or suspected low-grade infiltrating glioma on imaging. Given
the known biological diGerences between adult and childhood
gliomas, in addition to the diGerent logistic challenges and
economic aspects of imaging adult and paediatric populations, this
review addresses adults with glioma.
Types of interventions
Pre- or post-treatment brain imaging, including MRI and other types
of imaging, performed at regular intervals (interval or surveillance
imaging) compared with pre- or post-treatment brain imaging
performed upon the development of new or worsening symptoms
(symptomatic or triggered imaging) or other imaging schedules,
such as hybrids, with a defined surveillance hiatus.
Types of outcome measures
Primary outcomes
• Overall survival (as time-to-event or dichotomous outcomes or
both)
Secondary outcomes
• Progression-free survival (as time-to-event or dichotomous
outcomes or both)
Interval brain imaging for adults with cerebral glioma (Review)
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• Health-related quality of life measured by a standardised
instrument, such as the European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30 or QLQ-BN20 (specific for
brain cancer), or the Functional Assessment of Cancer Therapy
scale (FACT)-G (general) or FACT-Br (specific for brain cancer)
• Anxiety, measured by a standardised instrument, such as the
Hospital Anxiety and Depression Scale (HADS)
• Depression, measured by a standardised instrument, such as
HADS and the Beck Depression Inventory (BDI)
• Economic data (cost, cost eGectiveness, cost utility and cost
benefits)
Search methods for identification of studies
Electronic searches
The Cochrane Gynaecological, Neuro-oncology and Orphan Cancer
(CGNOC) Information Specialist searched the following databases
on 26 April 2018 and topped up the search for us on the 18 June
2019.
• For intervention studies
* Cochrane Central Register of Controlled Trials (CENTRAL), in
the Cochrane Library;
* MEDLINE Ovid (from 1946 onwards);
* Embase Ovid (from 1980 onwards).
• For economic evidence
* MEDLINE Ovid (from 2015);
* Embase Ovid (from 2015);
* NHS Economic Evaluation Database (EED).
The EED database was searched up to the end of December 2014
(when the last records were added to that database) and MEDLINE
and Embase from 1 January 2015, as NHS EED already included
comprehensive searches of these databases prior to 2015. We
also considered relevant grey literature, such as health technology
assessments, reports and working papers, for inclusion.
Please refer to Appendix 1 for draH MEDLINE search strategies. We
did not apply language restrictions to any of the searches.
Searching other resources
We searched the following for ongoing studies.
• ClinicalTrials.gov (clinicaltrials.gov)
• International Clinical Trials Registry Platform (ICTRP)
(apps.who.int/trialsearch)
We used the 'related articles' feature of PubMed and handsearched
the reference lists of included studies to identify newly published
articles and additional studies of relevance. If through these
searches we had identified any ongoing studies that had not been
published, we planned to approach the principal investigators to
ask for an update on the study status and any available relevant
data.
Data collection and analysis
Selection of studies
The CGNOC Information Specialist downloaded all titles and
abstracts retrieved by electronic searching for intervention studies
to Endnote® and removed duplicates. Two review authors (GT and
TL) independently screened the remaining records on title and
abstract. For potentially eligible records, we obtained copies of
the full texts and independently assessed them for eligibility. The
two review authors resolved any disagreements by discussion.
We used Covidence to facilitate this study selection process and
documented reasons for exclusion accordingly.
In our search for economic evidence, two review authors
independently screened for eligible studies using the same
methods as above.
Data extraction and management
Intervention studies
Two review authors (TL and GT) independently extracted data from
the included intervention study to a pre-designed data extraction
form that included the following.
• Author contact details
• Country
• Setting
• Dates of participant accrual
• Funding source
• Inclusion and exclusion criteria
• Study design
• Study population and baseline characteristics
* number of participants enrolled;
* number of participants analysed;
* age of participants;
* gender of participants;
* type of glioma (low grade or high grade; tumour size,
molecular markers);
* type of glioma treatment (surgery; radiotherapy;
chemotherapy).
• Intervention details
* type of intervention (pre-specified, interval or surveillance
imaging), including whether it occurred pre-treatment or
post-treatment, the interval period, and the type of scan (e.g.
MRI);
* type of comparator (symptomatic imaging or other imaging
schedule), including indications for imaging, information on
the timing of the imaging (e.g. median time to first scan post-
treatment), and the type of scan.
• 'Risk of bias' assessment (see below)
• Duration of follow-up
• Primary outcome(s) of the study
• Review outcomes
* For time-to-event outcomes (overall and progression-free
survival), we planned to extract the hazard ratio (HR) with
its 95% confidence interval (CI) for time points as reported
by the study authors. We would have noted the definition
of progression and the procedure used to identify it. Where
reported, we also planned to extract dichotomous data for
these outcomes at author-specified time points.
* For dichotomous outcomes (e.g. death, anxiety, depression),
we extracted the number of participants in each treatment
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arm that experienced the outcome of interest and the
number of participants assessed.
* For continuous outcomes (e.g. quality-of-life scores, anxiety,
depression), we planned to extract the value and standard
deviation of the outcome of interest and the number of
participants assessed at the relevant time point in each
group. We also planned to extract change-from-baseline
score data where reported and to note the type of scale used.
* We planned to extract adjusted statistics where reported.
* Where possible, all data extracted were those relevant to
an intention-to-treat analysis, in which participants were
analysed in the groups to which they were assigned.
* We resolved diGerences between review authors by
discussion or by appeal to a third review author when
necessary.
Studies of economic evaluation
We developed a data extraction form for economic evaluations
based on the format and guidelines used to produce structured
abstracts of economic evaluations for inclusion in the NHS
Economic Evaluation Database (NHS EED), adapted to the specific
requirements of this review. In addition to the outcomes described
above, we planned to extract the following data.
• Type of evaluations
• Sources of eGectiveness data
• Cost data
• Sources of cost data
• Sources of outcome valuations
• Analytical approach
Assessment of risk of bias in included studies
For studies of clinical eGects, we assessed the risk of bias of the
included study using Cochrane's tool and the criteria specified
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2017). This included assessment of:
• random sequence generation;
• allocation concealment;
• blinding of participants and healthcare providers;
• blinding of outcome assessors;
• incomplete outcome data (more than 20% missing data
considered high risk);
• selective reporting of outcomes;
• other possible sources of bias, such as lack of a power
calculation, baseline diGerences in group characteristics.
We assessed according to whether there was a risk of bias for the
following criteria.
• How participants were selected or allocated to the intervention/
comparison groups.
• Whether the intervention participants were representative of
the population of interest.
• Whether the comparison participants were representative of the
population of interest.
• Whether diGerences between the intervention and comparison
groups were controlled for or absent.
• Any other risk of bias.
Two review authors (TL and GT) assessed risk of bias independently
and resolved any diGerences by discussion. We summarised
judgements in a 'Risk of bias' table along with the characteristics of
the included study and interpreted the review results in light of the
overall 'Risk of bias' assessment. For more details about assessing
risk of bias, see Appendix 2.
Economic evaluations would be assessed for bias in two stages.
The first stage would involve assessing risk of bias from the sources
of the eGectiveness data. We would assess economic evaluations
carried out alongside clinical studies using the Cochrane 'Risk of
bias' tool, as described above. If the economic evaluation was
model-based, we would use the ROBIS tool to assess bias in the
eGectiveness studies (Whiting 2016). The second stage involves
assessing the risk of bias of the economic evidence (i.e. assessing
the overall methodological quality). We would use the CHEERS
and Evers checklists to do this (hsr.mumc.maastrichtuniversity.nl/
consensus-health-economic-criteria-chec-list), (Husereau 2013;
Thielen 2016; Van Mastrigt 2016; Wijnen 2016).
Measures of treatment e;ect
We only found data for dichotomous outcomes, for which we
calculated the eGect size as a risk ratio (RR) with its 95% CI.
Unit of analysis issues
Two review authors (TL and GT) would have reviewed unit
of analysis issues according to the criteria presented in Deeks
2017 and would have resolved any disagreements by discussion.
Unit of analysis issues might have included reports where there
were multiple observations for the same outcome (e.g. repeated
measurements with diGerent scales or at diGerent time points,
recurring events).
Dealing with missing data
We did not impute missing data. In the event of missing data, we
planned to write to study authors to request the data and describe
in the 'Characteristics of included studies' tables how any missing
data were obtained.
Assessment of heterogeneity
We planned to assess heterogeneity between intervention studies
in each meta-analysis by visual inspection of forest plots; by
estimation of the percentage heterogeneity between studies that
cannot be ascribed to sampling variation (Higgins 2003); by a
formal statistical test of the significance of the heterogeneity (Deeks
2008); and, where possible, by subgroup analyses. If there was
evidence of substantial heterogeneity, we would have investigated
and reported the possible reasons for it.
Assessment of reporting biases
If there were 10 or more intervention studies in meta-analyses we
planned to investigate reporting biases (such as publication bias)
using funnel plots and planned to assess asymmetry visually. If
asymmetry was suggested by a visual assessment, we planned to
perform exploratory analyses to investigate it (Sterne 2017).
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Data synthesis
For interventions studies
We planned to conduct meta-analyses if we judged participants,
comparisons and outcomes to be suGiciently similar to ensure
an answer that was clinically meaningful. We planned to use
the random-eGects model with inverse variance weighting for all
meta-analyses. If any studies had multiple intervention groups, we
planned to divide the ‘shared’ comparison group into the number
of treatment groups and comparisons between each treatment
group, and treat the split comparison group as independent
comparisons. We planned to perform meta-analysis of the results
assuming that we found at least two included studies that were
suGiciently similar for the findings to be clinically meaningful. When
a meta-analysis was not possible due to the availability of single
studies only, we planned to enter the data from single studies
into Review Manager 5 (Review Manager 2014), without totals, and
grade the findings as described below.
For studies of economic evaluation
We planned to summarise characteristics and results of included
economic evaluations using additional tables, supplemented by
a narrative summary that would compare and evaluate methods
used and principal results between studies. We would also tabulate
unit cost data, when available. We would report the currency and
price year applicable to measures of costs in each original study,
alongside measures of costs, incremental costs and incremental
cost eGectiveness, by study. Where details of currency and price
year were available in original studies, we would convert measures
of costs, incremental costs and cost eGectiveness to (latest year)
International Dollars value using implicit price deflators for gross
domestic product (GDP) and GDP purchasing power parities
(eppi.ioe.ac.uk/costconversion/default.aspx; Shemlit 2011). We
would summarise details of the methodological characteristics of
individual included health economics studies in the ‘Characteristics
of included studies’ tables. We would conduct all elements of
the economics component of this review according to current
guidance on the use of economics methods in the preparation and
maintenance of Cochrane Reviews (Shemlit 2011).
GRADE, 'Summary of findings' tables and results reporting
For evidence from intervention studies, based on the methods
described in Chapter 11 of the Cochrane Handbook for Systematic
Reviews of Interventions (Schünemann 2017a), we prepared a
'Summary of findings' table to present the results of the following
outcomes.
• Overall survival
• Progression-free survival
• Quality of life
• Anxiety
For each assumed risk cited in the tables, we provided a rationale,
and used the GRADE system to rank the quality of the evidence
(Schünemann 2017b). Where the evidence was based on single
studies, or where there was no evidence on a specific outcome,
we included the outcome in the 'Summary of findings' tables and
graded or explained accordingly. Two review authors would grade
the evidence together. We would consider downgrading evidence
of a clear eGect derived from single studies with small sample sizes
or few events and would resolve any diGerences of opinion by
discussion and, if necessary, by involving a third review author. We
planned to report the results of the meta-analyses in the text based
on the guidance from Cochrane EGective Practice and Organisation
of Care on review results reporting and interpretation (EPOC 2015).
For the economic evaluation evidence, we planned to present the
following findings in a table.
• Method of economic evaluation
• Costs
• Outcomes
• Incremental cost-eGectiveness ratio
Subgroup analysis and investigation of heterogeneity
For intervention studies, we planned to perform subgroup analysis
by the glioma grade (low grade and high grade) and molecular
markers, if possible. We planned to use formal tests for subgroup
diGerences to determine whether the eGect of interventions diGers
according to these subgroups. Depending on these findings, we
would consider whether an overall summary was meaningful. We
would have also considered factors such as age, gender, type of
treatment, and risk of bias in interpretation of any heterogeneity.
If we had identified substantial heterogeneity, we planned to
investigate it in sensitivity analyses.
Sensitivity analysis
For intervention studies, we planned to perform sensitivity analysis
to investigate substantial heterogeneity identified in meta-analyses
of primary outcomes and also to evaluate the eGect aHer excluding
studies at high risk of bias, to investigate how study quality aGects
the certainty of the findings.
R E S U L T S
Description of studies
Results of the search
Intervention study searches
Electronic searches for intervention studies yielded 1891
deduplicated records. Of these, we selected 57 studies on title and
abstract as potentially eligible studies. At this level of screening
we included paediatric studies and certain other studies that
would clearly be excluded based on study design because we
expected included studies to be few and wanted to identify as
many studies relevant to the research question as possible. We
subsequently found no studies (including an additional abstract
identified from the 2016 BNOS conference proceedings) that met
our study selection criteria and 58 studies were excluded. We
identified no eligible studies on www.ClinicalTrials.gov.
A subsequent top-up search conducted on 18 June 2019 yielded
173 records and led to the retrieval of two full texts: we included
Mrowczynski 2018 and excluded Zaazoue 2019. See Figure 1.
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Figure 1.   Study flow diagram.
 
Economic evaluation study searches
The electronic searches for studies of economic evaluation yielded
a list of 58 deduplicated records; of these, we identified one
study for potential eligibility. AHer examining the full text of
Heinzel 2012 we agreed that the evaluation was not assessing
imaging approaches for monitoring or follow-up but approaches
for diagnosis: we therefore excluded this study (i.e. we had not
identified any economic evaluations). A top-up search was carried
out in June 2019, which identified a further four records: one of
these was potentially eligible (Zaazoue 2019). We considered this
study for inclusion as, although it was a paediatric study, some of
the participants were over the age of 18. There was, however, no
specific subgroup analysis for participants over 18 and ultimately
we excluded the study. We therefore have no economic evaluations
to include.
Included studies
Intervention evaluation studies
Only one study was included (Mrowczynski 2018). This was a
retrospective series of 125 patients with GBM who were treated
at the Pennsylvania State University Department of Neurosurgery
between 2006 and 2016. The study compared early post-operative
MRI (within 48 hours of surgery) with no early post-operative
MRI. Patients were excluded if they had had a previous low-grade
glioma, and if date of death could not be accurately determined.
The primary outcome in this study was overall survival, which was
reported in terms of the probability of surviving one and two years,
and median survival in days. Mean age was approximately 60 years
overall, with slightly more men than women in the cohort. Most
patients were treated with maximal safe resection and received
radiotherapy (60 Gy) combined with temozolomide chemotherapy,
with approximately 80% in both imaging groups completing these
treatments. Just over half the patients (56%) also received adjuvant
temozolomide or another treatment (e.g. bevacizumab, Optune), or
both. The group characteristics were largely comparable between
the intervention arms, with a slightly lower mean age and higher
treatment completion rates in the early post-operative imaging
group than the no post-operative imaging group. Authors did not
report the timing of the first post-operative (pre-radiotherapy) MRI
in the 'no early post-operative imaging' group.
Economic evaluation studies
We identified no economic evaluations for this review.
Excluded studies
Intervention studies
We excluded the 59 studies (58 from the April 2018 search and one
from the June 2019 top-up search) for the following reasons.
• DiGerent study question (Albert 1994; Chang 2014; Chataway
1999; Danchaivijitr 2008; Farace 2013; Field 2017; Fujimura 2004;
Galban 2011; Gittleman 2016; Gorlia 2013; Klingelhofer 2015; Li
2011; Merkel 2017; Milano 2010; Patil 2017; Sreenivasan 2016;
Wick 2016).
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• Wrong type of study
* Case report (Cochereau 2016; Galldiks 2010; Singh 2012)
* Non-comparative case series (Gui 2018; Leonard 1975;
Lorimer 2017; Quinn 1971; Spitaels 2017)
* Other non-comparative study (Hamdan 2017; Mahaley 1983;
Meyers 2003; Scoccianti 2010; Seiz 2011; Wang 2009;
Weizman 2014)
* Review (Abrigo 2018; Christie 1975; Cihoric 2017; Fouke 2015;
Oberheim Bush 2016; Sanghera 2012; Shah 2011; Shiroishi
2013).
* Commentary/opinion paper (Easaw 2011; Macdonald 1990;
Neagu 2015; Reardon 2014; Sabattini 1980).
* Qualitative study (Geer 2012)
• Wrong study population (Ali 2014; de Graaf 2002; Kim 2014;
Korones 2001; Perreault 2014; Poussaint 2011; Saunders 2005;
Sethi 2011; Sutton 1996; Udaka 2012; Zaazoue 2019).
• Several studies had more than one reason for exclusion. For two
older studies (Aoyama 1982; Mueller 1981), we were unable to
obtain the full text.
In addition, we excluded Heinzel 2012 from the economic search as
it related to a diGerent study question, making the total number of
excluded studies 59.
Risk of bias in included studies
The only included intervention evaluation study was a non-
randomised retrospective study that we assessed as being at high
risk of bias overall, mainly due to high risk of selection bias
because the decision about whether or not a patient received
the intervention was leH to the preference and discretion of
the attending clinician (Mrowczynski 2018). Thus, intervention
groups might have been divided across diGerent practitioners
and have been managed diGerently. The study population was,
however, appropriate in terms of disease evaluated (GBM) and
treatment received; and available patient baseline characteristics
were comparable between the groups and any diGerences that
might have favoured better outcomes in the intervention group
(e.g. lower mean age) did not do so. Molecular information, early
re-operation for residual enhancing disease, and second line and
subsequent therapies were not reported. In addition, the reviewer
team had concerns about attrition bias from patients who did not
have their date of death recorded in the site's system, because the
number of patients eligible and included in the study from a 10-year
period at the neuro-oncology centre seemed low.
E;ects of interventions
See: Summary of findings for the main comparison
Evidence from intervention evaluation studies
Comparison: Early post-operative imaging versus no early post-
operative imaging
The evidence is derived from one included study only (Mrowczynski
2018).
Overall survival
Findings from the single study with 125 subjects suggested little or
no diGerence between early and no early post-operative imaging
with respect to the proportion of deaths at one year aHer diagnosis
(RR 0.86, 95% CI 0.61 to 1.21; 48% vs 55% had died, respectively;
very low certainty evidence; Analysis 1.1) or two years aHer
diagnosis (RR 1.06, 95% CI 0.91 to 1.25; 86% vs 81% had died,
respectively; very low certainty evidence; Analysis 1.2).
We found no data related to other review outcomes or comparisons.
Evidence from economic evaluation studies
There was no evidence regarding the cost-eGectiveness of diGerent
imaging strategies for monitoring glioma in adults.
D I S C U S S I O N
Summary of main results
This systematic review found one retrospective, comparative
study (125 patients) of early post-operative imaging compared
with no early post-operative magnetic resonance imaging for the
management of GBM. Evidence suggested that there may be
little or no diGerence with early imaging aHer surgery compared
with no early imaging in patient survival at one and two years
aHer diagnosis when the standard of care for GBM patients was
combined radiotherapy and temozolomide aHer maximal surgical
resection. However, we assessed the study as having a high risk of
bias for various reasons mainly related to its design, and hence we
assessed the evidence as very low quality/certainty.
We found no evidence on the comparative benefits and risks of
other types of imaging strategies that could inform guidance on the
optimal timing of surveillance imaging.
Overall completeness and applicability of evidence
There is little evidence to inform clinical practice guidelines with
respect to the eGectiveness of diGerent imaging strategies to
improve health outcomes among people with gliomas.
This review has identified no evidence to inform decision makers
on the eGiciency of diGerent imaging strategies in the management
of adults with glioma.
Quality of the evidence
The evidence on the relative eGectiveness of early post-operative
imaging is of very low quality/certainty and further research is
needed. Evidence on other imaging strategies is absent.
This review has identified no evidence on the cost eGectiveness
of diGerent imaging strategies in the management of adults with
glioma.
Potential biases in the review process
We followed Cochrane methodology for reviews of interventions
and are unaware of any potential biases in the review process.
We found only one comparative study of the diGerent imaging
approaches for GBM in the early post-operative interval, and none
for other types of glioma. We were unable therefore to synthesize
any evidence by meta-analysis. Although we found some studies
that had interesting data on imaging time points (for example,
from certain studies conducted in paediatric populations), none
fulfilled the review eligibility criteria and could inform the review
question directly. Whilst we considered deviating from the protocol
to allow for potential inclusion of these studies, we decided
rather to remain true to the protocol and discuss the strengths
and limitations of findings from these 'indirect' studies in the
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'Discussion' section of the review. This seemed appropriate
as Cochrane Reviews intrinsically evaluate quality/certainty of
evidence, and we considered that any evidence potentially derived
from such indirect studies would most likely be very low certainty
in the context of the review question. This is particularly the
case for paediatric studies, since the disease processes and issues
surrounding imaging, such as risk from anaesthesia and added
parental anxieties, are suGiciently diGerent from the context in
adults.
Whilst some might question the value of a relatively 'empty'
review with only one included study of limited quality, we
believed that identifying knowledge gaps in clinical practice is
as important as finding evidence to support a clinical practice.
Without identifying the knowledge gaps, meaningful discussions
and research planning on how high-quality studies can be designed
to fill the gaps are precluded.
Agreements and disagreements with other studies or
reviews
The primary aim of imaging in glioma management is to identify
definitive disease progression, as this leads to a change in
management. As with any surveillance examination, there will
be many visits in which no change of treatment is instigated.
To our knowledge, the first review that looked at potential
benefits of serial imaging in neuro-oncology was Christie 1975,
which introduced the concept that early transient changes do
not reflect true disease progression. A more recent systematic
review and evidence-based clinical practice guideline on low-
grade gliomas in adults did not attempt to answer questions
around the eGectiveness of imaging (Fouke 2015). One recent
review highlighted that trials of imaging are under-represented in
current research prioritisation (Cihoric 2017), and another called for
rigorous clinical evaluation of advanced imaging techniques that
might distinguish pseudoprogression and pseudoresponse from
true progression and response (Shiroishi 2013).
In the absence of evidence on imaging strategies for low-grade
gliomas, a few excluded studies deserve mention: Kim 2014 is
a paediatric study that demonstrates the type of research that
could potentially be undertaken in adults to generate evidence,
particularly since it considers both clinical and economic aspects
of imaging options. This retrospective study of 67 children with
recurrent grade 1 gliomas evaluated the timing and frequency
of post-operative imaging with respect to recurrence-free survival
and cost in the health system in the USA. Thirteen asymptomatic
recurrences occurred and all were detected by imaging, with a
mean time to recurrence of 32.4 months (ranging from 2.9 to 128.5
months). Comparing a standard imaging schedule (comprising an
MRI every 3 months for the first year, 6 months for the second year,
yearly until year 5 and then 2 to 3 yearly thereaHer) with a tailored,
less frequent schedule (comprising imaging at 0 months, 3 months,
1 year, 2 years, and 5 years aHer surgery), the authors found that the
less frequent schedule (5 scans instead of 10) was suGicient. It is not
known whether detection of asymptomatic recurrence improved
survival outcomes in this cohort, however, given the slow-growing
nature of the tumour. The authors proposed the less intensive
imaging schedule as having potential psychosocial and economic
benefits.
Similarly, another study conducted in the USA analysed
detection eGiciency of diGerent post-operative surveillance
imaging protocols for paediatric low-grade gliomas (Zaazoue 2019).
Based on retrospective data of 517 patients who underwent
8061 scans, they reported that an 8-image surveillance protocol
(comprising imaging at 0 months, 3 months, 6 months, 1 year,
2 years, 3 years, 5 years and 6 years) detected progression at
comparable rates to the 15-image protocol currently in practice in
that setting. For patients who underwent gross total resection, this
could be further reduced to six scans.
By comparison, for adults with less aggressive gliomas (excluding
grade 1) the post-operative imaging surveillance schedule currently
suggested by NICE comprises eight or nine scans in the first five
years aHer surgery. Thus retrospective reviews of adult data similar
to the paediatric studies could help to clarify whether this type of
schedule is eGective, particularly since numbers attainable from
several co-ordinated multi-centre and international clinical trials
would be larger than those available in paediatric practice.
With respect to high-grade gliomas another excluded study, the
findings of which were reported at the 2016 British Neuro-
Oncology Society conference and available in abstract form
only, compared recurrence detection rates of interval scans with
those of symptomatic scans among 38 GBM patients who had
completed the full standard of care chemoradiotherapy regimen
(Hamdan 2017). Authors reported that symptomatic scans (n =
12) detected more instances of recurrence than interval scans
(n = 145) in this selected group of patients (58.3% vs 22.7%,
respectively). In addition, none of these optimally treated patients
had disease progression aHer a fiHh stable routine interval
scan (presumably within the study period, which was 2004 to
2012). While comparing symptomatic and surveillance imaging,
these scans were being carried out in the same cohort, not
between two cohorts of diGerently-managed patients, and there
is no indication of whether this partitioning was done based on
actual clinical presence or absence of symptoms and signs, or
whether this was based on imaging being on or oG schedule -
some surveillance imaging is still performed when patients are
symptomatic or clinically worsening. There is also no indication of
how progressive disease was diagnosed, and whether confirmation
of progression on symptomatic imaging was back-dated to the
time of initial - sometimes asymptomatic - suspected progression,
as happens in clinical trials using response assessment in neuro-
oncology (RANO) criteria for example. The number of patients
(n = 38) and number of symptomatic scans (n = 12) are also
low, and there is no way to determine the diGerential impact
of symptomatic versus surveillance imaging on the summary
data included in the abstract. Surveillance imaging detected a
higher absolute number of progression events than symptomatic
imaging (33 versus 7, which of note does not sum to the quoted
number of 38 participants). There are no results presented which
address whether the asymptomatic progression was associated
with diGerent overall outcomes. However, mathematical modelling
using a larger database, as suggested by these authors, would
appear a reasonable approach to aid in determining the optimal
timing of interval scans for low- and high-grade gliomas. Such
modelling could use prognostic algorithms to stratify patients into
surveillance imaging pathways, and tailoring these pathways to risk
factors should optimise resource use (Perreault 2014).
Several studies have evaluated the predictive value of various
clinical (patient age, gender, performance status, extent
of resection, radiotherapy and chemotherapy) and tumour
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characteristics (location, volume, histopathology), as well as
imaging and molecular biomarkers (Gorlia 2013; Lorimer 2017;
Pignatti 2002; Rees 2009). Assessing individual tumour growth
rates through serial imaging in the first year aHer diagnosis could
also be helpful by distinguishing those low-grade gliomas that
have a higher risk of progression from those that are in a slow
growth phase (Gui 2018; Weizman 2014). A prognostic algorithm
that incorporates some or all these factors might, therefore, reliably
predict tumour behaviour and facilitate stratification of patients
into diGerent surveillance imaging pathways. It could also be
important to consider patient preferences as a component of
any potential algorithm. Whilst there is currently little known
about the potential adverse psychological eGects of surveillance
imaging, Kim 2014 and others have pointed out that less frequent
imaging might reduce its psychological burden, and hence might
be preferred by patients, although the obverse may also be the case
for some patients and carers who find regular imaging reassuring.
Preferences could be assessed in a future survey or study.
In most developed country settings, people receiving treatment for
glioma are encouraged to participate in clinical trials (NCCN 2018),
which oHen employ imaging to detect progressive disease at more
frequent intervals than suggested in clinical guidance. Thus, it may
be challenging to conduct a randomised trial solely to answer the
question of the optimal timing of imaging in glioma, particularly
if a comparison of generic schedules may be contrary to a more
individualised approach.
Finally, in addition to 'when' to image, 'how' to image needs
research. We may not be realising any benefit from early/
pre-symptomatic diagnosis of progression because we lack the
appropriate stratification tools and treatments. If we had improved
techniques that could detect meaningful changes in tumour
behaviour before any symptoms present, it might lead to improved
decision-making with regards to continuing or changing treatment
and subsequently better patient outcomes. One such example is
2-hydroxyglutarate (2HG) magnetic resonance spectroscopy, which
can provide a non-invasive biomarker of IDH mutation status and
could be used to inform follow-up approaches (Leather 2017).
Biopsies of blood or cerebrospinal fluid may also be used to
direct such decisions as this technology improves (Shankar 2017).
In the future, these could complement (or even partly replace)
surveillance imaging and should be borne in mind in the design of
future studies.
Economic evidence
There is a paucity of evidence regarding the eGiciency and cost
eGectiveness of diGerent imaging strategies. We found no studies
that examined the cost eGectiveness of diGerent imaging strategies
for monitoring and follow-up of adults with glioma but there
was one excluded study that built a decision model assessing
diGerent imaging strategies for diagnosing glioma (Heinzel 2012).
This study used a decision tree model to assess whether the cost
eGectiveness of the combined use of 18F-fluoroethyl-L-tyrosine
(FET) PET and MRI may be superior to MRI alone. The study
concludes that the combined strategy had an 18.5% increase in the
likelihood of correct diagnosis. If the time horizon of this model
could be extended for the entire course of the disease, the costs
and benefits of these two imaging strategies could be explored.
Another excluded study examined post-operative interval imaging
in a paediatric population (Zaazoue 2019). The study concluded
that fewer post-operative surveillance imaging intervals were
necessary to manage low-grade glioma in a paediatric population
compared to standard practice. As discussed above the post-
operative imaging surveillance schedule for adults suggests at
least eight scans. If these results were generalisable to an adult
population this could result in a more eGicient use of imaging
resources in the health care system. Future studies modelling the
disease progression with diGerent imaging strategies and intervals
would aid decision makers in understanding the optimum way to
manage adults with glioma from the perspective of both the patient
and the health care system.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Current approaches to imaging gliomas are based on plausibility
and pragmatism through expert consensus rather than a body
of high-level research evidence. It remains unknown whether
identification of progression through surveillance imaging instead
of symptomatic imaging improves glioma survival or other health
outcomes. Limited evidence suggesting that early post-operative
brain imaging among GBM patients who receive combined
chemoradiation treatment could make little or no diGerence
to survival needs robust assessment through further research,
particularly as early post-operative imaging also serves as a quality
control measure that may lead to early re-operation if residual
tumour is identified.
We expect that as further evidence on prognostic indicators
comes to light, it might be possible to stratify people with
glioma to diGerent imaging schedules based on assessment of
tumour behaviour and other prognostic factors particular to each
individual. A clear example of this would be the recognition of
molecular high-risk, histologically low-grade glioma, which would
be managed as per GBM. In the absence of good-quality evidence
on the eGectiveness and optimal frequency of surveillance
imaging, a multi-disciplinary team approach and shared decision-
making is essential in the context of existing broad consensus
recommendations.
Implications for research
There are eGorts across neuro-oncology to standardise or
harmonise both the type and timing of imaging although, as
described above, this is not based on any high-quality evidence.
Researching management of gliomas is challenging because it
is an uncommon disease covering a variety of age groups and
prognostic types, for some of whom the optimal treatment strategy
remains uncertain. There is also the added challenge of a shiHing
diagnostic and prognostic landscape with recent additions of
molecular characterisation which is expected to expand in the
near future. Collaborative, multicentre studies are now considered
essential to suGiciently power relevant clinical questions. There
is also the philosophical challenge of investigating higher versus
lower frequency imaging; particularly in the oncology sphere,
where in general there is an evolution in management aimed at
replacing or adding to regimens rather than removing from them.
There are relevant precedents, however, including alterations to
surveillance imaging practice, such as regular chest radiographs
and bone scintigraphy in breast cancer having demonstrated a
lack of value (Lam 2017), and the paediatric studies discussed
above, which recommended a significant reduction in the follow-up
imaging schedule. It should be possible to prospectively determine
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a research paradigm into imaging schedules in glioma in the era of
shared decision-making.
It would also be of potential value to retrospectively evaluate
individual patient data from trials that have been conducted in the
post-Stupp regimen RANO era for GBM, given the natural jitter in
timing of follow-up (i.e. not every patient is imaged precisely at 3-
monthly intervals), missed or delayed imaging visits for a variety of
reasons, and diGerent imaging frequencies in trials (e.g. 2- versus
3-monthly) that likely have used the Stupp regimen in their control
arms. These data could be analysed to determine if there are any
impacts on outcome of diGerent imaging schedules. Challenges to
this would include the exclusion of any trial participants if being
imaged oG schedule represents a protocol violation and avoiding
selection bias of those eligible to enter trials.
Advanced imaging techniques to identify true progression (and not
pseudoprogression) and true response (not pseudoresponse) also
require rigorous evaluation in the relevant clinical contexts.
Other research questions for high-grade gliomas are as follows.
• Based on clinicoradiological or molecular markers (or both), can
high-grade gliomas be stratified into diGerent interval imaging
schedules to rationalise the frequency of imaging visits?
• What is the impact of interval imaging frequency on time to
progression during first line treatment?
• How does interval imaging aGect the entry to second line trials?
• Does the frequency of interval imaging influence overall
survival?
• What are the cost eGectiveness and diagnostic performance
of additional imaging (e.g. MRS/perfusion/permeability MRI/
PET) to determine response to treatment when progression is
suspected in order to minimise repeated standard MRI during
the current period of diagnostic uncertainty?
Other research questions for low-grade gliomas are as follows.
• Based on clinicoradiological or molecular markers (or both), can
low-grade gliomas be stratified into diGerent interval imaging
schedules to rationalise the frequency of imaging visits (e.g. IDH
mutation status from 2HG spectroscopy)?
• Does interval imaging lead to earlier detection of progression
and malignant transformation?
• Does interval imaging influence overall survival?
• What are the cost eGectiveness and diagnostic performance of
additional imaging (e.g. MRS/perfusion/permeability MRI/PET)
to stratify patients into diGerent prognostic groups requiring
diGerent imaging schedules?
To improve decision-making and promote good practice and
external validity, protocols of future studies on imaging should
adhere to prevailing guidance (e.g. CONSORT, QUADAS and STARD)
to ensure the quality of the study, and should include economic
and psychosocial outcomes whenever possible, in this era of shared
decision-making.
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Characteristics of included studies [ordered by study ID]
 
Methods Design: retrospective series from a single institution
Country: USA
Accrual dates: 2006 to 2016
Trial reg: N/A
Funding: N/R
Participants No. analysed: 125
Inclusion/exclusion criteria: all patients with GBM at the Pennsylvania State University Department of
Neurosurgery between 2006 and 2016 were included unless they had had a previous low-grade glioma,
and if date of death could not be accurately determined
Age: mean 59.98 (range 5 to 82)
Gender: 53% male, 47% female
Glioma type: GBM
Glioma grade: 4
Treatment: most patients were treated with maximal safe resection and received radiotherapy (60 Gy)
combined with temozolomide chemotherapy, with approximately 80% in both imaging groups com-
pleting these treatments. Just over half the patients (56%) also received adjuvant temozolomide or
other treatment (bevacizumab, Optune)
Interventions Arm 1: post-operative imaging within 48 hours of resection based on surgeon preference and discretion
(n = 69)
Arm 2: no post-operative imaging (n = 56)
Outcomes Overall survival at 1 year and 2 years; median survival
Notes It is not clear in the report when patients in Arm 2 had their first post-operative MRI, i.e. for radiation
planning.
Risk of bias
Bias Authors' judgement Support for judgement
Selection bias High risk "The decision of post-operative imaging was largely based on surgeon prefer-
ence and discretion."
Intervention participants
representative
Low risk These were patients with GBM, most of whom received chemoradiation after
maximal resection.
Mrowczynski 2018 
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Comparison participants
representative
Low risk These were patients with GBM, most of whom received chemoradiation after
maximal resection.
Baseline differences ab-
sent or controlled for
Unclear risk Baseline patient characteristics are comparable and any differences that
might favour better outcomes in the intervention group (e.g. lower mean age
and slightly less treatment completion) did not do so. However, there was no
information on molecular characteristics.
Other bias Unclear risk Because the number of patients eligible and included in the study from a 10-
year period at the neuro-oncology centre seemed low, the reviewer team had
concerns about possible attrition bias arising from patients who did not have
their date of death recorded in the site's system.
Mrowczynski 2018  (Continued)
N/A: not applicable
N/R: not reported
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abrigo 2018 Wrong type of study ‒ a diagnostic test accuracy review of magnetic resonance perfusion.
Albert 1994 Wrong study question ‒ a non-comparative observational study on early post-operative imaging.
Ali 2014 Wrong study population ‒ a study conducted in children with suspected LGG.
Aoyama 1982 Unable to obtain full text.
Chang 2014 Wrong study question ‒ this observational study aimed to evaluate the survival difference between
early- versus late-diagnosed progressive disease.
Chataway 1999 Wrong study question ‒ a retrospective analysis of an MRC trial that compared the predictive value
of two different clinically-assessed scores (not imaging techniques/intervals) for determining pro-
gression.
Christie 1975 Wrong type of study ‒ an older review of brain imaging.
Cihoric 2017 Wrong type of study ‒ a review of registered trials in GBM management (see Agreements and dis-
agreements with other studies or reviews).
Cochereau 2016 Wrong type of study ‒ a case report of one case reflecting that progression can occur without clini-
cal manifestation.
Danchaivijitr 2008 Wrong study question ‒ a prospective cohort study looking at correlation between cerebral blood
volume changes and malignant transformation.
de Graaf 2002 Wrong study population ‒ a non-comparative study in children on the predictive role of clinical as-
sessment to inform symptomatic imaging.
Easaw 2011 Wrong type of study ‒ this is a guideline consensus paper that concluded that the optimal timing of
MRI after chemoradiation has not been established.
Farace 2013 Wrong study question ‒ this is a non-comparative observational study looking at whether another
imaging time point is needed before starting adjuvant treatment in GBM.
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Study Reason for exclusion
Field 2017 Wrong study question ‒ a substudy of an RCT looking at the prognostic association of early pro-
gression on MRI among recurrent GBM patients receiving bevacizumab vs bevacizumab plus carbo-
platin.
Fouke 2015 Wrong type of study ‒ a review of the role of imaging in the management of glioma.
Fujimura 2004 Wrong study question ‒ a retrospective study of pre-operative MRI imaging vs no pre-operative MRI
imaging in the elderly. Control group is historical and only a single pre-operative time point is mea-
sured (i.e. it is not about interval imaging or symptomatic imaging).
Galban 2011 Wrong study question ‒ a study that looked at a new MRI technique to predict outcomes and facili-
tate earlier second-line treatment decisions.
Galldiks 2010 Wrong type of study ‒ a study of two GBM patients who underwent complex PET imaging.
Geer 2012 Wrong type of study ‒ qualitative study about whether perfusion MRI increased confidence in diag-
nosis and management plan.
Gittleman 2016 Wrong study question ‒ a study to design a nomogram to predict survival in GBM.
Gorlia 2013 Wrong study question ‒ a study on prognostic indicators for survival in grade 3 gliomas.
Gui 2018 Wrong type of study ‒ a retrospective case series on the growth pattern/dynamics of slow-growing
tumours.
Hamdan 2017 Wrong type of study ‒ a retrospective study reporting the proportion of symptomatic (12 scans)
and interval MRIs (145 scans) that detected disease progression in a group of 38 fully treated
glioblastoma patients.
Heinzel 2012 Wrong intervention ‒ a cost-effectiveness study of a decision tree model of imaging for diagnosis
(not monitoring and follow-up) of glioma
Kim 2014 Wrong study population ‒ a retrospective cohort study on the frequency and timing of post-opera-
tive imaging.
Klingelhofer 2015 Wrong study question ‒ prognostic study of MRI versus histology to predict survival.
Korones 2001 Wrong study population ‒ retrospective study among children with low- or high-grade gliomas to
quantify the proportion of asymptomatic progression.
Leonard 1975 Wrong type of study ‒ one of the earliest papers to show asymptomatic biological progression of
brain tumours.
Li 2011 Wrong study question ‒ prognostic study that examines serial MRI for stratifying patients. There are
potential imaging implications from the findings.
Lorimer 2017 Wrong type of study ‒ retrospective case series of elderly people with GBM.
Macdonald 1990 Wrong type of study ‒ a report on formalised clinical radiological response criteria to identify tu-
mour response to treatment.
Mahaley 1983 Wrong type of study ‒ a substudy of a clinical trial of levisamole in which all participants received
serial CT scans. Authors concluded that, for first 6 months, clinical findings were most useful for re-
sponse assessment, and that (CT) imaging could be started from 6 months. Cost of CT influenced
conclusions.
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Study Reason for exclusion
Merkel 2017 Wrong type of study ‒ a prognostic study that found that 60% of GBM patients are early progressors
and the timing of imaging pre-chemoradiotherapy should needs formal research.
Meyers 2003 Wrong type of study ‒ a retrospective study of 56 patients with recurrent brain tumours that were
recruited to clinical trials and who had scans at regular intervals — usually monthly — and cogni-
tive function testing. Cognitive deterioration preceded radiographic evidence of tumour progres-
sion by 6 weeks on average, suggesting that clinical surveillance using cognitive domain scoring
might be of value in addition to other follow-up measures to identify progression.
Milano 2010 Wrong study question ‒ a study of the patterns of recurrence of GBM, and not about imaging.
Mueller 1981 Unable to obtain this paper.
Neagu 2015 Wrong type of study ‒ an opinion paper on management of GBM, with discussion around advanced
imaging at follow-up but nothing on the frequency of follow-up (see Agreements and disagree-
ments with other studies or reviews).
Oberheim Bush 2016 Wrong type of study ‒ a review of treatment strategies for LGG.
Patil 2017 Wrong study question ‒ an RCT of video follow-up versus clinical follow-up of people with glioma.
Perreault 2014 Wrong study population ‒ a study of surveillance imaging in children with CNS tumours, which dis-
cusses the role of tailoring spinal MRI according to the risk of spinal relapse to improve the alloca-
tion of resources.
Poussaint 2011 Wrong study population ‒ a retrospective study of data from 2 clinical trials conducted among chil-
dren with brainstem glioma that employed frequent MRI surveillance (post-op and every 8 weeks in
year 1, 3-monthly thereafter, and at the end of treatment or disease progression); however, no evi-
dence for the number of images obtained and their timeframe was given.
Quinn 1971 Wrong type of study ‒ an older case series of 14 patients that introduces the concept of serial imag-
ing in GBM management.
Reardon 2014 Wrong type of study ‒ this is a consensus report that does not address frequency of imaging; rather,
it is more concerned with increasing the accuracy of imaging to identify progression. Authors sug-
gest introducing more complex imaging (at the very least T1w subtraction maps) but not reducing
imaging frequency.
Sabattini 1980 Wrong type of study ‒ this is an older opinion paper that proposes a protocol for serial CT scans
(before and after surgery, before chemo-radiotherapy and after each treatment cycle) based on the
authors' experience.
Sanghera 2012 Wrong type of study ‒ a review on distinguishing pseudoprogression from true progression in pa-
tients with glioblastoma
Saunders 2005 Wrong study population ‒ a retrospective study on surveillance imaging strategies conducted
among children with cerebellar astrocytoma, which discusses the frequency and timing of surveil-
lance imaging in this context.
Scoccianti 2010 Wrong type of study ‒ a retrospective pattern of care study about changes in GBM care over time in
Italy.
Seiz 2011 Wrong type of study ‒ a survey of diagnosis and treatment practices related to LGG in Germany,
which revealed an approximate 50:50 split over 'wait and see' and early intervention approaches.
Sethi 2011 Wrong study population ‒ a retrospective non-comparative study of 16 paediatric patients with dif-
fuse intrinsic pontine glioma who underwent serial 4-monthly neuraxial MRIs. Authors concluded
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Study Reason for exclusion
that it led to a high detection rate of leptomeningeal dissemination (and earlier intervention) and
suggested that such serial scanning should therefore be considered in future clinical trials.
Shah 2011 Wrong type of study ‒ a systematic review of the management of incidental suspected LGG. Au-
thors conclude that "the asymptomatic patient may be monitored safely with serial MR imaging
and occasionally PET scanning before treatment is initiated." The 'optimal treatment paradigm'
proposed includes serial MRI every 4 months.
Shiroishi 2013 Wrong type of study ‒ a review on post-treatment assessment of central nervous system tumours
that highlights issues such as pseudoprogression and pseudoresponse and the need for rigorous
clinical evaluation of promising advanced imaging techniques such as perfusion MR, diffusion MR
and permeability MR imaging, MR spectroscopy and PET in this context.
Singh 2012 Wrong type of study ‒ a case report of a glioma patient with pseudoprogression and clinical deteri-
oration on treatment.
Spitaels 2017 Wrong type of study ‒ a case series describing the management of 35 people with recurrent diffuse
LGG.
Sreenivasan 2016 Wrong study question ‒ a retrospective archive-based study that evaluated glioma volume mea-
surement techniques.
Sutton 1996 Wrong study population ‒ a retrospective study of the records of 93 children with cerebellar astro-
cytomas from 1975 to 1993, which suggested that routine surveillance imaging might not be neces-
sary in completely resected tumours because recurrence is small; however, it is probably of value
in incompletely resected tumours.
Udaka 2012 Wrong study population ‒ a restrospective case series of 102 children with LGG, which suggests
that routine surveillance imaging up to 5 years is beneficial, even for completely resected tumours.
Authors suggest the possibility of shortening the imaging protocol, which may represent some
form of rationalisation, but not reducing the number of visits (i.e. just reducing the time taken for
each). The median number of scans per year in this study was 3.4.
Wang 2009 Wrong type of study ‒ a mathematical modelling paper based on 32 patients with GBM aimed at
stratifying GBM by behaviour.
Weizman 2014 Wrong type of study ‒ this study of 10 patients with LGGs evaluates different techniques for track-
ing the progress of slow-growing tumours.
Wick 2016 Wrong study question ‒ substudy of an RCT of bevacizumab added to chemoradiation looking at
pseudoprogression rates and tumour progression patterns.
Zaazoue 2019 Wrong study population ‒ paediatric population
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Comparison 1.   Early post-surgery imaging vs no early imaging
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall survival (deaths at 1
year)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 HGG 1 125 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.61, 1.21]
1.2 LGG 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2 Overall survival (deaths at 2
years)
1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 HGG 1 125 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.91, 1.25]
2.2 LGG 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Early post-surgery imaging vs no
early imaging, Outcome 1 Overall survival (deaths at 1 year).
Study or subgroup Early post-
op imaging
No early post-
op imaging
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 HGG  
Mrowczynski 2018 33/69 31/56 100% 0.86[0.61,1.21]
Subtotal (95% CI) 69 56 100% 0.86[0.61,1.21]
Total events: 33 (Early post-op imaging), 31 (No early post-op imaging)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.84(P=0.4)  
   
1.1.2 LGG  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Early post-op imaging), 0 (No early post-op imaging)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours early scan 1000.01 100.1 1 Favours no early scan
 
 
Analysis 1.2.   Comparison 1 Early post-surgery imaging vs no
early imaging, Outcome 2 Overall survival (deaths at 2 years).
Study or subgroup Early post-
op imaging
No early post-
op imaging
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 HGG  
Mrowczynski 2018 59/69 45/56 100% 1.06[0.91,1.25]
Subtotal (95% CI) 69 56 100% 1.06[0.91,1.25]
Total events: 59 (Early post-op imaging), 45 (No early post-op imaging)  
Heterogeneity: Not applicable  
Favours early scan 1000.01 100.1 1 Favours no early scan
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Study or subgroup Early post-
op imaging
No early post-
op imaging
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.75(P=0.45)  
   
1.2.2 LGG  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Early post-op imaging), 0 (No early post-op imaging)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours early scan 1000.01 100.1 1 Favours no early scan
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Years after end of treatmentTumour grade
0 to 1 1 to 2 2 to 3 3 to 4 5 to 10 > 10 (for the rest of life)
Grade 1 Scan at 12 months, then:
• consider discharge if no tumour visible on imaging unless completely resected pilocytic astrocytoma
• consider ongoing imaging at increasing intervals for 15 years for completely resected pilocytic as-
trocytoma
• consider if ongoing imaging is needed at a rate of once every 1 to 3 years for the rest of the person's
life if the tumour is visible on imaging
Grade II 1p/19q non-
codeleted, IDH mutated
Grade II 1p/19q codeleted
Grade III 1p/19q codeleted
Scan at 3 months, then every
6 months
Annually Every 1 to 2
years
Consider ongoing imag-
ing every 1 to 2 years
Grade II IDH wildtype
Grade III 1p/19q non-
codeleted
Grade IV (glioblastoma)
Every 3 to
6 months
Every 6 to
12 months
Annually Consider ongoing imag-
ing
every 1 to 2 years
Table 1.   National Institute for Health and Clinical Excellence (NICE) guidance on interval imaging  (Continued)
From NICE 2018 (p17) Table 3: Possible regular clinical review schedule for people with glioma depending on grade of tumour
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Appendix 1. MEDLINE search strategy
MEDLINE strategy
1. exp Glioma/
2. (glioma* or astrocytoma* or ependymoma* ganglioglioma* or gliosarcoma* or oligodendroglioma* or glioblastoma* or
oligoastrocytoma* or GBM*).ti,ab.
3. 1 or 2
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4. neuroimaging/
5. exp Magnetic Resonance Imaging/
6. (MRI or MRi or magnetic resonance imag*).ti,ab.
7. (brain* adj5 (imag* or scan*)).ti,ab.
8. Tomography, X-Ray Computed/
9. ((CT or CAT or compute* tomograph*) adj5 (scan* or imag*)).ti,ab.
10. exp Positron-Emission Tomography/
11. (positron-emission tomography* or PET).ti,ab.
12. exp Magnetic Resonance Spectroscopy/
13. (magnetic resonance spectroscop* or MR*).ti,ab.
14. contrast-enhanced computerised tomography or CT.ti,ab.
15. Perfusion Imaging/
16. exp Tomography, Emission-Computed, Single-Photon/
17. SPEC or SPECT.ti,ab.
18. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 3 and 18
20. ((inter* or routin* or regular* or frequen* or sequential or continuous* or serial* or recur*or longitudinal* or repeat*) adj5 (scan* or
imag*)).ti,ab.
21. 19 and 20
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
DraN MEDLINE strategy with economic filter
1. exp Glioma/
2. (glioma* or astrocytoma* or ependymoma* ganglioglioma* or gliosarcoma* or oligodendroglioma* or glioblastoma* or
oligoastrocytoma* or GBM*).ti,ab.
3. 1 or 2
4. neuroimaging/
5. exp Magnetic Resonance Imaging/
6. (MRI or MRi or magnetic resonance imag*).ti,ab.
7. (brain* adj5 (imag* or scan*)).ti,ab.
8. Tomography, X-Ray Computed/
9. ((CT or CAT or compute* tomograph*) adj5 (scan* or imag*)).ti,ab.
10. exp Positron-Emission Tomography/
11. (positron-emission tomography* or PET).ti,ab.
12. exp Magnetic Resonance Spectroscopy/
13. (magnetic resonance spectroscop* or MR*).ti,ab.
14. contrast-enhanced computerised tomography.mp. or CT.ti,ab. [mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier,
synonyms]
15. Perfusion Imaging/
16. exp Tomography, Emission-Computed, Single-Photon/
17. SPEC.mp. or SPECT.ti,ab. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
18. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19. 3 and 18
20. ((inter* or routin* or regular* or frequen* or sequential or continuous* or serial* or recur*or longitudinal* or repeat*) adj5 (scan* or
imag*)).ti,ab.
21. 19 and 20
22. Economics/
23. exp "costs and cost analysis"/
24. Economics, Dental/
25. exp economics, hospital/
26. Economics, Medical/
27. Economics, Nursing/
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28. Economics, Pharmaceutical/
29. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
30. (expenditure$ not energy).ti,ab.
31. value for money.ti,ab.
32. budget$.ti,ab.
33. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. ((energy or oxygen) adj cost).ti,ab.
35. (metabolic adj cost).ti,ab.
36. ((energy or oxygen) adj expenditure).ti,ab.
37. 34 or 35 or 36
38. 33 not 37
39. letter.pt.
40. editorial.pt.
41. historical article.pt.
42. 39 or 40 or 41
43. 38 not 42
44. 21 and 43
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
Appendix 2. Assessment of risk of bias
For randomised controlled trials
We will assess the risk of bias according to the following criteria.
(1) Random sequence generation
• Low risk of bias e.g. participants assigned to treatments on basis of a computer-generated random sequence or a table of random
numbers
• High risk of bias e.g. participants assigned to treatments on basis of date of birth, clinic ID-number or surname, or no attempt to
randomise participants
• Unclear risk of bias e.g. not reported, information not available
(2) Allocation concealment
• Low risk of bias e.g. where the allocation sequence could not be foretold
• High risk of bias e.g. allocation sequence could be foretold by participants, investigators or treatment providers
• Unclear risk of bias e.g. not reported
(3) Blinding of participants and personnel
• Low risk of bias if participants and personnel were adequately blinded
• High risk of bias if participants and/or personnel were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
(4) Blinding of outcome assessors
• Low risk of bias if outcome assessors were adequately blinded to the intervention that the participant received
• High risk of bias if outcome assessors were not blinded to the intervention that the participant received
• Unclear risk of bias if this was not reported or unclear
(5) Incomplete outcome data
We will record the proportion of participants whose outcomes were not reported at the end of the study. We will code a satisfactory level
of loss to follow-up for each outcome as:
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• low risk of bias, if fewer than 20% of participants were lost to follow-up and reasons for loss to follow-up were similar in both treatment
arms
• High risk of bias, if more than 20% of participants were lost to follow-up or reasons for loss to follow-up diGered between treatment arms
• Unclear risk of bias if loss to follow-up was not reported
(6) Selective reporting of outcomes
• Low risk of bias e.g. review reports all outcomes specified in the protocol
• High risk of bias e.g. It is suspected that outcomes have been selectively reported
• Unclear risk of bias e.g. It is unclear whether outcomes had been selectively reported
(7) Other bias
• Low risk of bias, i.e.no other source of bias suspected and the study appears to be methodologically sound
• High risk of bias: we suspect that the study was prone to an additional bias
• Unclear risk of bias: we are uncertain whether an additional bias may have been present
For non-randomised controlled trials and controlled before-aNer studies
We will assess the risk of bias in accordance with four criteria concerning sample selection comparability of treatment groups:
(1) Relevant details of criteria for assignment of patients to treatments
• Low risk of bias, e.g. yes, details provided
• High risk of bias, e.g. no details provided
• Unclear risk of bias, e.g. details unclear
(2) Representative group of people who received the experimental intervention
• Low risk of bias, if representative of participants with low and/or high grade gliomas who receive interval brain imaging to assess their
condition
• High risk of bias, if groups of participants were selected (non-consecutive)
• Unclear, if selection of the group was not described
(3) Representative group of people who received the comparison intervention
• Low risk of bias, if drawn from the same population as the experimental group
• High risk of bias, if drawn from a diGerent source
• Unclear risk of bias, if selection of group not described
(4) Baseline di6erences between groups controlled for, in particular with reference to age, gender, grade of glioma and glioma
treatment
• Low risk of bias, if at least three of these characteristics were reported
• High risk of bias, if the groups diGered in these baseline characteristics and diGerences were not controlled for
• Unclear risk of bias, if fewer than three of these characteristics were reported even if there were no other diGerences between the groups,
and other characteristics were controlled for
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